KINGDON CAPITAL MANAGEMENT CORP
SC 13D, 1997-01-21
Previous: NORTH AMERICAN SCIENTIFIC INC, 10KSB40, 1997-01-21
Next: ADMINISTAFF INC DE, S-1/A, 1997-01-21






<PAGE>

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

SCHEDULE 13D
Under the Securities Exchange Act of 1934

Amendment No.:  *

Name of Issuer:  Xomed Surgical Products, Inc.

Title of Class of Securities:  Common Stock, $.01 par value

CUSIP Number:  98412V107

          (Name, Address and Telephone Number of Person
       Authorized To Receive Notices and Communications)  

 Mr. Peter J. Cobos c/o Kingdon Capital Management Corporation,
 152 West 57th Street, New York, New York 10019, (212) 333-0100

     (Date of Event which Requires Filing of this Statement)

                        January 10, 1997

If the filing person has previously filed a statement on Schedule
13G to report the acquisition which is the subject of this
Schedule 13D, and is filing this schedule because of
Rule 13d-1(b)(3) or (4), check the following box [   ].

Check the following box if a fee is being paid with this
statement [].  (A fee is not required only if the filing person:
(1) has a previous statement on file reporting beneficial
ownership of more than five percent of the class of securities
described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of
class.  See Rule 13d-7).

*The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment
containing information which would alter the disclosures provided
in a prior cover page.

The information required in the remainder of this cover page
shall not be deemed to be "filed" for the purpose of Section 18
of the Securities Exchange Act of 1934 ("Act") or otherwise
subject to the liabilities of that section of the Act but shall
be subject to all other provisions of the Act (however, see the
Notes).



<PAGE>

CUSIP No. 98412V107

1.  Name of Reporting Person
    S.S. or I.R.S. Identification No. of Above Person

         Kingdon Capital Management Corporation  #13-3158796

2.  Check the Appropriate Box if a Member of a Group

         a.   
         b.   x

3.  SEC Use Only

4.  Source of Funds

         WC

5.  Check if Disclosure of Legal Proceedings is Required Pursuant
    to Items 2(d) or 2(e)

6.  Citizenship or Place of Organization

         Delaware

Number of Shares Beneficially Owned by Each Reporting Person
With:

7.  Sole Voting Power:

         400,000

8.  Shared Voting Power:


9.  Sole Dispositive Power:

         400,000

10. Shared Dispositive Power:


11. Aggregate Amount Beneficially Owned by Each Reporting Person

         400,000

12. Check Box if the Aggregate Amount in Row (11) Excludes
    Certain Shares





                               -2-



<PAGE>

13. Percent of Class Represented by Amount in Row (11)

         5.51%

14. Type of Reporting Person

         CO

Item 1.  Security and Issuer

         This statement relates to shares of common stock, par
         value $.01 per share (the "Common Stock") of Xomed
         Surgical Products, Inc. ("XOMD").  XOMD's principal
         executive office is located at 6743 Southpoint Drive N.,
         Jacksonville, FL 32216.

Item 2.  Identity and Background

         This statement is being filed on behalf of Kingdon
         Capital Management Corporation ("KCMC"), a Delaware
         corporation.  KCMC's principal business is to act as an
         investment adviser; its principal office is at 152 West
         57th Street, New York, New York 10019.

         Mr. Mark Kingdon is the sole shareholder, director and
         executive officer of KCMC.  Mr. Kingdon has not, during
         the last five years, been convicted in a criminal
         proceeding (excluding traffic violations or similar
         misdemeanors).  Mr. Kingdon has not, during the last
         five years, been a party to a civil proceeding of a
         judicial or administrative body of competent
         jurisdiction which resulted in a judgment, decree or
         final order enjoining future violations of, or
         prohibiting or mandating activities subject to, federal
         or state securities laws or finding any violations with
         respect to such laws.

         Mr. Kingdon is a citizen of the United States of
         America.

Item 3.  Source and Amount of Funds or Other Consideration.

         As of the date hereof, KCMC beneficially owns 400,000
         shares of Common Stock.  All 400,000 shares of Common
         Stock are held by entities and managed accounts over
         which KCMC has investment discretion.  The 400,000
         shares of the Common Stock were purchased in open market
         transactions at an aggregate cost of $7,749,673.80.  The
         funds for the purchase of the Common Stock held in the
         entities and managed accounts over which KCMC has
         investment discretion have come from each entity's or


                               -3-



<PAGE>

         account's own funds.  No leverage was used to purchase
         any shares.

Item 4.  Purpose of Transactions.

         The shares of Common Stock beneficially owned by KCMC
         were acquired for, and are being held for, investment
         purposes.

         KCMC has no plan or proposal which relates to, or would
         result in, any of the actions enumerated in Item 4 of
         the instructions to Schedule 13D.

Item 5.  Interest in Securities of Issuer.

         As of the date hereof, KCMC is the beneficial owner of
         400,000 shares of Common Stock.  Based on XOMD's most
         recent filing on Schedule 10-Q on November 25, 1996, as
         of November 20, 1996 there were 7,259,000 shares of
         Common Stock outstanding.  Therefore, KCMC is deemed to
         beneficially own 5.51% of the outstanding shares of
         Common Stock.  KCMC has the sole power to vote, direct
         the vote, dispose of or direct the disposition of all
         the shares of Common Stock that it is currently deemed
         to beneficially own.

Item 6.  Contracts, Arrangements, Understandings or
         Relationships with Respect to Securities of the Issuer

         KCMC has no contract, arrangement, understanding or
         relationship with any person with respect to the Common
         Stock.

Item 7.  Material to be Filed as Exhibits.

         Attached hereto as Exhibit A is a description of the
         transactions in the Common Stock that were effected by
         KCMC during the 60 days prior to January 10, 1997.















                               -4-



<PAGE>


    Signature

         The undersigned, after reasonable inquiry and to the
         best of its knowledge and belief, certifies that the
         information set forth in this statement is true,
         complete and correct.

January 21, 1997



Kingdon Capital Management Corporation


By: /s/ Peter J. Cobos        

    __________________________
    Peter J. Cobos, Controller


































                               -5-



<PAGE>

                            EXHIBIT A

                    SCHEDULE OF TRANSACTIONS

Date               Shares Purchased    Price Per Share
                      or (Sold)        (Not Including Commission)
____               _______________     ______________________

1/10/97                105,000             $12.81

1/10/97                 45,000              12.10










































                               -6-
48400002.AG3



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission